понедельник, 21 марта 2016 г.

Analysts Start to Turn Against Valeant After Worst Day Ever

Analysts Start to Turn Against Valeant After Worst Day Ever


One of Valeant Pharmaceuticals International Inc.'s biggest sell-side supporters downgraded her rating on the company's stock Wednesday, following other analysts who are starting to turn against the drugmaker after a 51 percent drop in the shares Tuesday. Shibani Malhotra, an analyst with Nomura Securities, cut her rating on the shares to neutral and gave a $60 12-month price target.



from Biotech News